Form 4: Rigel Pharmaceuticals Director Sells Shares
Statement of Changes in Beneficial Ownership
Rigel Pharmaceuticals Director Kamil Ali-Jackson sold 2,500 shares of common stock on June 22, 2026, as part of a pre-arranged 10b5-1 trading plan to cover tax withholding obligations.
Summary
- Kamil Ali-Jackson, a Director at Rigel Pharmaceuticals Inc., sold 2,500 shares of common stock on June 22, 2026.
- The transaction was executed under a Rule 10b5-1 trading plan adopted on November 7, 2025.
- The sale was to cover tax withholding obligations related to the vesting of restricted stock units.
- The shares were not sold for investment purposes.
- Following the transaction, the reporting person beneficially owns 10,125 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine insider transaction for tax purposes under a pre-established plan, with no indication of positive or negative company performance.
Future Outlook
No specific future outlook or guidance is provided in this filing.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently signal company performance, but rather adherence to regulatory requirements for reporting ownership changes.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| 10b5-1 Trading Plan | The transaction was executed under a Rule 10b5-1 trading plan adopted by the Reporting Person. | 11/07/2025 | Ensures compliance with insider trading regulations by establishing a pre-arranged plan for stock sales. |
Stakeholder Impact
- Shareholders: The sale is part of a pre-arranged plan to cover tax obligations, not an indication of a change in the director's investment thesis in Rigel Pharmaceuticals.
Key Dates
| Date | Description |
|---|---|
| 11/07/2025 | Date of adoption of the Rule 10b5-1 trading plan. |
| 06/22/2026 | Date of the reported stock sale transaction. |
| 06/24/2026 | Date of the signature on the Form 4 filing. |
Keywords
Rigel Pharmaceuticals, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Director Transaction, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.